NL-OMON48384已完成不适用
Capsaicin pain model with topical 1% ethanolic capsaicin solution - 1% capsaicin solution pain model
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Healthy male subjects, 18 to 45 years of age, inclusive. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs. ;2. Body mass index (BMI) between 18 and 30 kg/m2, inclusive. ;3. Able to participate and willing to give written informed consent and to comply with the study restrictions.
排除标准
- •1. History or symptoms of any significant disease including (but not limited to), neurological, psychiatric, endocrine, cardiovascular, respiratory, gastrointestinal, hepatic, or renal disorder. ;2. Clinically significant abnormalities, as judged by the Investigator, in laboratory test results (including hepatic and renal panels, complete blood count, chemistry panel and urinalysis). In the case of uncertain or questionable results, tests performed during screening may be repeated before randomization to confirm eligibility or judged to be clinically irrelevant for healthy subjects. ;3. History of alcohol or drug abuse;4. Participation in an investigational drug or device study within 3 months prior to screening. ;5. Any confirmed significant allergic reactions (urticaria or anaphylaxis) after previous exposure to capsaicin ;6. Subject indicating intolerable pain after capsaicin administration at screening;7. Any current, clinically significant, known medical condition in particular any existing conditions that would affect sensitivity to cold (such as atherosclerosis, Raynaud*s disease, urticaria, hypothyroidism) or pain (i.e., disease that causes pain, hypesthesia, hyperalgesia, allodynia, paraesthesia, neuropathy) ;8. Subjects indicating pain tests intolerable at screening or achieving tolerance at >80% of maximum input intensity for any pain test for cold, pressure and electrical tests.;9. Dark skin (Fitzpatrick skin type V - VI), wide-spread acne, tattoos or scarring on the volar forearms.
研究者
相似试验
尚未招募
不适用
1% capsaicin solution pain modelNL-OMON20584CHDR10
进行中（未招募）
1 期
Treatment of nerve pain in patients with diabetes with a capsaicin (chilli pepper) patch (skin plaster).EUCTR2017-004746-17-GBJoint Research Compliance Office, Imperial College London and Imperial College Healthcare NHS Trust50
已完成
不适用
Validation of the capsaicin (1%) sensitization model in the context of the PainCart test batterypainNeuropathic painNL-OMON45379Centre for Human Drug Research38
招募中
1 期
CAPSAPEDChronic postchirurgical or post-traumatic neuropathic painMedDRA version: 21.0Level: LLTClassification code: 10054095Term: Neuropathic pain Class: 10029205CTIS2022-500265-27-00Centre Hospitalier Regional Et Universitaire De Brest46
已完成
3 期
The role of topical capsaicin gel in pain management during microfocused ultrasound treatment for neck laxityneck skin laxityAnesthesia, Chili, Lidocaine, Nociceptive pain, Prilocaine, TRPV1 receptorTCTR20220225006Division of Dermatology, Department of medicine, Faculty of Medicine, Ramathibodi hospital24